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Background: Mesenchymal stem cells (MSCs) are the cells which have high renewal capacity and and are capable for 
differentiating into some types of cells. MSCs can be obtained from several tissues including bone marrow, synovial 
membrane, blood, adipose tissue and periosteum. The proliferation and self-repair ability of MSCs are the advantages to use 
as stem cells-based therapy of various diseases. The aim of this study was to determine the differentiation, characterization 
and proliferation of synovial membrane-derived MSCs (SM-MSCs). 
Materials and Methods: The cells proliferation capacity was determined by cell counting using trypan blue, characterization 
of MSCs (cluster of differentiation (CD)90, CD11b, CD73, CD34, CD19, CD45, CD105 and human leukocyte antigen-DR 
isotype (HLA-DR)) using flow cytometry analysis, and differentiation capability into three lineage cells was determined with 
red alcian blue, oil red O and alizarin staining.
Results:  The type culture of SM-MSCs was adherent and showed positive CD44, CD105, CD73, CD90 and negative of 
CD19, HLA-DR, CD11b, CD45, CD34 surface marker. Based on the result, SM-MSCs P3 showed differentiation potency into 
adipogenic, chondrogenic, and osteogenic lineage cells. The population doubling time of SM-MSCs has increased from P3 
to P8. The population doubling time of SM-MSCs P3 was 1.69 days and SM-MSCs P8 was 3.64 days.
Conclusion: The results indicated that SM-MCSCs from osteoarthritis patients are able to differentiate into osteocytes, 
chondrocytes, adipocytes  and highly express of CD105, CD73, CD90, CD44 and negative for CD34, CD45, CD14, CD19.
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Introduction
Osteoarthritis (OA) is the most common disease in the joints 
associated with disability and pain.1 The prevalence of OA 
increases due to aging and an increase in related factors such 
as obesity. Radiographic evidence of knee OA is present in 
about 30% of men and women over the age of 65 years. 
Estimates around the world are that 9.6% of men and 18.0% 
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of women over the age of 60 have symptomatic OA. About 
80% of those with OA will have limitations in movement, 
and 25% cannot carry out their daily activities.2,3 OA is one 
of degenerative diseases in old age population. The disease 
damage joints and bones around it, and leading to chronic 
disability.4 The main target of OA is cartilage tissue, and the 
starting point for OA is cartilage damage or loss.5 The rate 
of chondrocytes regeneration as the component of cartilage 
tissue was decreased in older people6, as a result, therapy is 
needed to cure OA. Unfortunately, the existing OA therapy 
has been used drugs administration and surgery for total 
joint replacement.7 This therapy is not effective because 
long-term drug administration causes negative effects on the 
other organs such as cardiovascular, kidneys, and digestive 
system.8,9 Consequently, an alternative therapy is necessary 
to regenerate damaged articular cartilage.
 Chondrocytes are the main cellular component of 
cartilage, which is widely used for OA treatment.Autologous 
chondrocytes implantation (ACI) is a biomedical treatment 
cell-based for OA patients, the procedure takes place in 
three stages including cartilage isolation, cell grown in 
vitro and cell implantation to patient.10 But this therapy still 
has various disadvantages, for example surgery that causes 
cartilage damage, dedifferentiation in chondrocytes and has 
lower regeneration potency.11 Therefore, another approach 
is required for regeneration of cartilage in OA patients.
 Stem cells can be used in tissue regeneration, for stem 
cells have the ability to differentiate and self-renew at the 
time of embryonic stage, in which cells can proliferate into 
tissue or certain organs during the developmental process.12 
Mesenchymal stem cells (MSCs) can differentiate into 
adipocytes, chondrocytes and osteocytes.13,14 MSCs can be 
isolated from various sources such as bone marrow (BM-
MSCs), adipose tissues (AT-MSCs), umbilical cords (UC-
MSCs), Wharton's jelly (WJ-MSCs), synovial tissues (ST-
MSCs), and other tissues.15,16 
 MSCs isolated from synovial membrane (SM) have 
ability to differentiate into chondrocytes that very suitable 
for cartilage regeneration therapy. MSCs are able to fuse 
with cartilage defects, proliferate, regenerate articular 
cartilage, reduce the concentration of synovial fluid from 
prostaglandin17 and reduce the progressiveness of OA.18 
Future research should be directed at addressing the gap 
in diagnostics and therapy for OA. Hence, research on the 
potential of SM from OA patients in its use as autologous 
therapy necessary to be done. The objective of this study was 
to determine the character, differentiation and proliferation 
of synovial cells of membranes P4 and P8 isolated from 
patients with OA.
Materials and methods
MSCs Isolation from SM
SMs were obtained from three knee in patients with OA from 
Dr. M. Djamil Hospital, Padang, Indonesia. The patients 
have signed the informed consent using the guidelines 
approved by Research Ethics Committee, Faculty of 
Medicine, Universitas Andalas, Padang, Indonesia (No. 226/
KEP/FK/2019). SMs then washed using phosphate buffer 
saline (PBS) (Catalogue #14200075, Gibco, Massachusetts, 
USA), 1% antibiotic and antimycotic (ABAM) (Catalogue 
#15240062, Gibco) and 1% Amphotericin B (Catalogue 
#15290026, Gibco). SMs were cut into small pieces and 
washed, cleased from skin and fat. The synovial membranes 
were put into centrifuge tube (Catalogue #50015, SPL, 
Pocheon, South Korea) containing Collagenase enzyme type 
I (Catalogue #17100017, Gibco), Hyaluronidase (Catalogue 
#H-3506, Sigma Aldrich, Massachusetts, USA) and Trypsin-
EDTA 0.1% (Catalogue #25200072, Gibco). The tube 
stored in CO2 resistant shaker (Catalogue #SHKE2000CO2, 
Thermo Fisher Scientific, Massachusetts, USA) at 300 rpm 
for 16 hours in the incubator (Catalogue #8000DH, Thermo 
Fisher Scientific) of 5% CO2 and 37°C.16 The remaining 
SM was removed, and the supernatant was centrifuged 
(MPW-260R, Warsaw, Poland) at 1600 rpm for 5 minutes. 
The supernatant was removed, and the pellet was mixed 
with complete medium: Mem-α (Catalogue #32561037, 
Gibco) which supplemented by 10% Fetal Bovine Serum 
(FBS) (Catalogue #10270106, Gibco), and 1% ABAM, 
1% Amphotericin B addition. SM-MSCs was cultured at 
density of 2x106 cells in T-flask 25cm2 (Catalogue #90026, 
TPP, Trasadingen, Switzerland). The cells were incubated 
on T-flask 25cm3 at 5% CO2 and 37°C incubator.19
 
SM-MSCs Surface Markers Characterization
The SM-MSCs reached 80% confluence were harvested for 
analyzing the positive and negative cluster differentiation 
(CD) markers (Fowcytometry analyzer 10, Macsquant, 
California, USA). The cells were stained with hMSCs 
analysis kit (Caltalogue#562245, BD stem flowTM Kit, 
New Jersey, USA) and the procedure was according to the 
manufacture protocol. The experiments and measurement 
were performed in triplicate.18,20
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Differentiation Capability of SM-MSCs
The osteogenic differentiation, SM-MSCs (P4 and P8) were
seeded at density 5x103 in 24 well plate (Catalogue #142475, 
Nunc, Massachusetts, USA)  using StemPro Osteogenesis 
Differentiation Kit  (Catalogue #A10072-01, Gibco) for 3 
weeks. Osteocytes  were visualized using Alizarin Red S 
(Catalogue #A5533, Sigma Aldrich). 
 The chondrogenic differentiation, SM-MSCs (P4, 
P8) were seeded 5x103 cells 24 well plate  using StemPro 
Chondrogenesis Differentiation Kit (Catalogue# A10071-
01, Gibco) for 3 weeks. Chondrocytes were confirmed using 
Alcian blue (Catalogue#A5268, Sigma Aldrich).   
 Adipogenic differentiation of SM-MSCs was executed 
by StemPro Adipogenic Differentiation Kit (Catalogue 
#A10070-01, Gibco) for 3 weeks. To confrim lipid droplets 
in the culture as the marker of adiponic differentiation using 
Oil Red O staining (Catalogue #00625, Sigma Aldrich).13,21
Population Doubling (PD) Time of SM-MSCs
P4-P8 of SM-MSCs in T75 flask were detached by 3 mL 
of trypsin-EDTA 0.25% (Catalogue #25200072, Gibco) and 
was incubated at 5% CO2 and 37°C incubator for 3 minutes. 
The complete medium was added to stop the trypsin and 
the cells were centrifugated at 1600 rpm for 5 minutes. The 
obtained pellet was added with 1 mL complete medium. 
The cells were counted by a hemocytometer (Catalogue 
#17849, Neubauer,  Lauda-Königshofen, Germany) using 
1:1 Trypan Blue (Catalogue #T8154, Sigma Aldrich) as the 
stain. PD was counted at every passage with formula: PD = 
LOG (Harvest/Seeded)/ LOG2.22 Meanwhile, the PD time 
(PDT) was determined by this formula: PDT = t (time)/PD 
(in days).18
Statistical Analysis
Statistical was analyzed with Statistical Package for the 
Social Sciences (SPSS) statistics version 20.0 software 
(IBM Corporation, New York, USA). Value was provided as 
mean±standard deviation. Significant diversity between the 
groups were determined using the analysis of variance (One 
Way ANOVA) followed by Tukey’s HSD Post-hoc test.
Results
SM-MSCs Characteristic 
Figure 1 showed the culture SM-MSCs at P4 as the result 
of cells isolation from OA patients. SM-MSCs exhibited 
adherent of culture, resulted, and elongated in spindle-
shaped cells. SM-MSCs exhibited adherent type of culture, 
elongated and resulted in spindle-shaped cells. In Figure 2 
and Table 1, SM-MSCs that was isolated from OA patients 
at P4 and P8 showed negative expression for CD34, CD11b, 
CD45, CD19 and HLA-DR, yet showed high expression 
for CD44, CD90, CD73 and CD105. The two different 
passages, P4 (early) and P8 (intermediate) of the cells 
showed no difference CD markers expression. Both P4 
and P8 were detected to have the same level expression of 
certain positive and negative surface markers.
Differentiation of MSCs
The result of SM-MSCs differentiation into 3 different types 
of cells. They were chondrocyte, adipocyte, and osteocyte 
as shown in Figure 3. There was no difference result of 
differentiation between P4 and P8 from the qualitative 
staining result. Osteogenic showed positive result by the red 
color and confirmed by the accumulation of calcium deposit 
which detected by Alizarin Red S. Glycosaminoglycan as 
well as the marker of chondrogenesis could be identified 
with Alcian Blue staining as specific polyvalent dye that 
was used to identify acidic polysaccharides. As can be seen 
in the Figure 3, the cells were associated in the process of 
chondrogenic differentiation and stained as blackish blue. 
Oil Red O was used as a dye in adipogenic differentiation 
which was characterized by the formation of oil droplets. 
Oil Red O was a diazo dye that was used to stain the lipid 
formation and triglycerides.10,19, 20,22
PDT of SM-MSCs
PDT and cumulative population doubling (CPD) data were 
shown in Table 2. SM-MSCs isolated from the synovial 
Figure 1. P4 of SM-MSCs culture with adherent 
characteristic . White bar: 200 mm.
79
Print ISSN: 2527-4384, Online ISSN: 2527-3442DOI: 10.21705/mcbs.v4i2.100Molecular and Cellular Biomedical Sciences, Vol.4 No.2, July 2020, p.76-82
Figure 2. The dot blot 
expression marker of SM-
MSCs analyzed by flow 
cytometer.  SM-MSCs 
was confirmed as MSCs 
with high expression for 
positive marker, CD90: 
92.59%; CD73: 95.67%, 
and CD105: 98.33%. MSCs 
also low expression of 
negative lineage. SM-MSCs 
also exhibited positive 
expression for CD44 as the 
additional CD markers to 
define MSCs.
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Passage CD90 CD44 CD105 CD73 Negative Lineage
P4 92.52±0.15 87.02±0.58 98.34±0.02 95.15±0.59 0.42±0.18
P8 92.59±0.11 87.88±0.49 98.33±0.02 95.67±0.42 0.72±0.18
Table 1. The different eggect of passages toward surface markers of SM-MSCs.
Data are presented as mean±standard deviation of surface markers of SM-MSCs. Negative lineage 
marker containing CD45, CD34, CD11b, CD19 and HLA-DR.
shows that PDT and CPD increase along with the increase 
of passage and was significantly different among the 
passages except the 5th and the 6th passage were defined 
as not significantly different at p<0.05. The PDT and CPD 
can be seen in Table 2 and were used to measure the MSCs 
proliferation capacity and define as a specific time for cells 
to undergo the cell division. PDT from P3-P8 was ranged 
1.69 to 3.64 days.
Discussion
SM-MSCs from the knee of OA patient with grade IV 
are used because they are waste that is not used anymore. 
OA patient with grade IV has low quality of stemness, 
MSCs  quantity and quality decrease with aging, limiting 
the potential efficacy of MSCs for therapy the elderly 
population.21 We try to develop method by utilizing waste 
materials and low quality. There are 3 basic criteria of the 
cells to be characterized as MSCs based on the International 
Society for Cellular Therapy, such as: 1) have differentiation 
capability into osteocyte, adipocyte, and chondrocyte; 2) 
Passage PDT (d) CPD
P3 1.69±0.04a 1.69
P4 1.79±0.02b 3.46
P5 2.36±0.03c 5.82
P6 2.33±0.03c 8.15
P7 3.15±0.01d 11.3
P8 3.64±0.03e 14.94
Table 2. PDT and CPD of SM-MSCs.
Data were presented as mean±standard 
deviation. Different small letters (a,b,c,d,e) 
in the same column are significant at p<0.05 
(Tukey HSD post hoc test).
have the adherent type of culture; 3) have positive expression 
for several CD markers such as CD44, CD73, CD90, and 
CD105 and showed negative expression for CD45, CD14, 
CD34, and HLA-DR.21-24  Markers characterization of the 
cells results in same finding with the previous study showed 
that the MSCs isolated different sources was also showed 
high expression of CD73, CD44, CD90, CD105 and low 
expression of CD19, CD45, CD34, CD14 and HLA-II 
both early (P4) and intermediate passage (P8).13,22,25 It also 
appropriate with previous study that MSCs from various 
sources, such as AT-MSCs had positive markers for CD90, 
CD73, and CD105. AT-MSCs had negative markers of CD14 
or CD11b, CD34, CD19, CD45, and HLA-DR in their cell-
surface immunophenotyped. Several studies also proved 
that MSCs have positive surface marker of CD44..22,26,,27 
The cells isolated from SM of OA patients also conformed 
with previous study which SM-MSCs had positive CD44.26
 According to the results, the cells isolated from the 
SM was considered as MSCs be able to differentiate into 
3 types of cells (osteocyte, chondrocyte, adipocyte). Thus, 
the method has succesfully used to produce SM-MSCs and 
considered as the first step of application mediated therapy 
for OA patiens. 
 The PDT and CPD difference in the 5th and the 6th 
passage might caused by the proliferation capacity of cells 
were decreased at the higher passage. As indicated by 
MSCs derived from other sources such as BM-MSCs and 
AT-MSCs have relative shorter culture time, the cell growth 
was slower at P10-P11, at P14-P16 in umbilical cord blood 
MSCs (UCB-MSCs).28 The PDT result are supported by 
previous research which explained that WJ-MSCs induced 
by normoxia and hypoxia 2,5% and 5% have increase in 
proliferation time from early passage to older passage.22 
The validation SM-MSCs from various grade OA patients is 
needed to confirm the isolation and characterization method. 
The validation of SM-MSCs for OA therapy  in animal is 
needed to continue models should eventually follow for 
further study. 
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A.  Differentiation of SM-MSCs
B.   Negative Control
P4
P8
P4
P8
A1
A2
B1
B2
C1
C2
D1
D2
E1
E2
F1
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Figure 3. Morphology analysis of osteogenic, chondrogenic,  adipogenic differentiation of SM-MSCs  at P4 and P8. A1: 
Differentiation adipocytes P4; A2: Differentiation adipocytes P8; B1: Differentiation chondrocytes P4; B2: Differentiation 
chondrocytes P8; C1: Differentiation osteocytes P4; C2: Differentiation osteocytes P8; D1: Control adipocytes P4; D2: 
Control adipocytes P8; E1: Control chondrocytes P4; E2: Control chondrocytes P8; F1: Control osteocytes P4; F2: Control 
osteocytes P8.
Conclusion
The results of this experiment indicated that SM-
MSCs isolated from OA patients has been successfully 
characterized. SM-MSCs have high expression of CD90, 
CD44, CD105, CD73 and low expression of CD34, 
CD45, CD14, CD19, HLA-II, be able to differentiate into 
osteocyte, chondrocyte, adipocyte and have the adherent 
type of culture. 
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